中国P站

Migraine pathogenesis is understood as a complex interplay of neurovascular and genetic factors, with current research highlighting cortical spreading depression as a primary initiator. This process triggers the activation of the trigeminal nerve, leading to the release of crucial neuropeptides like CGRP [1].

Calcitonin gene-related peptide (CGRP) plays a central role in migraine pathophysiology, mediating vasodilation and pain transmission within the trigeminovascular system. The success of blocking CGRP or its receptor in therapeutic interventions underscores its critical involvement in both acute attacks and migraine prevention [2].

Genetics significantly influences migraine susceptibility, with numerous identified genes impacting neuronal excitability, neurotransmitter signaling, ion channel function, and vascular regulation. Polymorphisms in genes associated with familial hemiplegic migraine, such as those affecting ion channels, exemplify this genetic contribution [3].

Cortical spreading depression (CSD) is increasingly recognized as a pivotal event in migraine, particularly in cases with aura. CSD involves a wave of neuronal depolarization propagating across the cerebral cortex, causing transient neuronal dysfunction and potentially triggering subsequent events [4].

The trigeminovascular system is fundamental to migraine pain. Activation of the trigeminal nerve results in the release of pro-inflammatory neuropeptides that cause cranial blood vessel dilation and neurogenic inflammation, sensitizing pain pathways [5].

Neuroinflammation, involving glial cells and inflammatory mediators, is crucial in the chronicization and persistence of migraine pain. Activated glial cells contribute to central sensitization, increasing pain sensitivity [6].

Ion channels are central to migraine pathophysiology, particularly in familial hemiplegic migraine. Defects in genes encoding ion channels can lead to neuronal hyperexcitability and are directly linked to CSD and migraine attacks [7].

The brainstem, including the periaqueductal gray and trigeminal nucleus caudalis, is vital for migraine pain modulation. Dysregulation of descending pain inhibitory pathways originating from the brainstem may contribute to migraine [8].

The hypothalamic-pituitary-adrenal (HPA) axis and its role in stress response are often altered in individuals with chronic migraine. Stress is a known trigger, and HPA axis dysfunction may exacerbate migraine susceptibility and chronification [9].

Mitochondrial dysfunction is a potential factor in migraine, especially in conditions like MELAS syndrome. Impaired energy production and increased oxidative stress due to mitochondrial defects can lead to neuronal hyperexcitability and contribute to migraine symptoms [10].

Description

The pathophysiology of migraine is characterized by a complex interplay of neurovascular and genetic elements. Cortical spreading depression is identified as a key initiating event, triggering the trigeminal nerve and the release of neuropeptides such as CGRP [1].

Calcitonin gene-related peptide (CGRP) serves as a central mediator in migraine. Its role in vasodilation and pain transmission within the trigeminovascular system is significant, and therapies targeting CGRP have proven highly effective, highlighting its importance in migraine management [2].

Genetic predispositions are substantial contributors to migraine susceptibility. Numerous genes involved in neuronal excitability, neurotransmitter systems, ion channels, and vascular regulation have been implicated. Specific gene variations are linked to distinct migraine subtypes, such as familial hemiplegic migraine [3].

Cortical spreading depression (CSD) is a critical phenomenon in migraine pathogenesis, particularly for migraine with aura. This wave of depolarization across the cortex induces transient neuronal dysfunction, which can subsequently activate the trigeminal nerve and contribute to migraine symptoms [4].

The trigeminovascular system is central to the experience of migraine pain. Activation of the trigeminal nerve leads to the release of various neuropeptides, including CGRP, substance P, and neurokinin A, which induce vasodilation and neurogenic inflammation, ultimately sensitizing pain pathways [5].

Neuroinflammation, involving the activation of glial cells like astrocytes and microglia, plays a significant role in the chronification of migraine. These inflammatory processes contribute to central sensitization, making individuals more sensitive to pain stimuli [6].

Ion channel function is intrinsically linked to migraine, especially in genetically determined forms like familial hemiplegic migraine. Mutations in genes encoding critical ion channels can result in neuronal hyperexcitability and are associated with CSD, providing direct evidence for the role of ion channel dysfunction [7].

Brainstem structures, including the periaqueductal gray and the trigeminal nucleus caudalis, are essential in the modulation and processing of migraine pain. Alterations in descending pain inhibitory pathways originating from the brainstem are believed to be involved in migraine pathophysiology [8].

The hypothalamic-pituitary-adrenal (HPA) axis, integral to the body's stress response, frequently exhibits dysregulation in individuals with chronic migraine. The bidirectional relationship between stress and HPA axis activity is considered a contributing factor to migraine development and chronification [9].

Mitochondrial dysfunction has emerged as a potential contributor to migraine, particularly in certain genetic disorders. Impaired cellular energy production and increased oxidative stress associated with mitochondrial defects can lead to neuronal hyperexcitability and manifest as migraine symptoms [10].

Conclusion

Migraine is a complex neurological disorder influenced by a combination of neurovascular, genetic, and inflammatory factors. Key mechanisms include cortical spreading depression, which initiates trigeminal nerve activation and neuropeptide release, notably CGRP. Genetic predispositions significantly impact susceptibility, with ion channel and neurotransmitter gene variations playing a crucial role. Neuroinflammation involving glial cells contributes to the chronicization of pain. The trigeminovascular system is central to pain signaling, while brainstem structures modulate pain processing. Stress, mediated by the HPA axis, is a significant trigger, and mitochondrial dysfunction may also contribute to the pathophysiology. Understanding these interconnected mechanisms is vital for developing effective therapeutic strategies.

References

1. Anil K, Priya S, Rajesh G. (2023) .J Pain Relief 12:15-28.

   , ,

2. Sumit S, Pooja M, Amit V. (2022) .J Pain Relief 11:45-59.

   , ,

3. Deepak J, Renu S, Vikram P. (2024) .J Pain Relief 13:78-92.

   , ,

4. Navjot K, Jaspreet S, Gurdeep S. (2023) .J Pain Relief 12:30-42.

   , ,

5. Harshita A, Mohit G, Sunita S. (2022) .J Pain Relief 11:60-75.

   , ,

6. Pankaj K, Sunaina D, Abhishek S. (2023) .J Pain Relief 12:101-115.

   , ,

7. Ruchi V, Anmol G, Komalpreet K. (2022) .J Pain Relief 11:20-35.

   , ,

8. Manish S, Kriti G, Neetu S. (2024) .J Pain Relief 13:116-130.

   , ,

9. Sunil K, Priya A, Deepak V. (2023) .J Pain Relief 12:50-65.

   , ,

10. Rajesh S, Anjali S, Amit K. (2022) .J Pain Relief 11:90-105.

    , ,